BRAF, and microsatellite instability (MSI)/mismatch repair deficiency (dMMR) testing for all patients with metastatic colorectal cancer (mCRC), among the study’s 1497 patients with mCC, a subset of mCRC, the testing rates were 41%, 43%, and 51%, respectively. Of...
Purpose of Review Molecular testing for lung cancer has evolved dramatically over the last decade, driven primarily by the rapid development of targeted therapies. Initial testing was intended to make appropriate therapeutic choices with primary single gene testing and has evolved into larger sensitive ...
Molecular testing is a critical component of the treatment selection process in lung cancer, as a host of effective drugs have since been developed to target alterations such as ALK, ROS1, and RET, according to Yujie Zhao, MD, PhD, who added that the integration of RNA-based sequ...
Molecular genetic analysis is an integral part of colorectal cancer (CRC) management. The choice of systemic therapy for CRC is largely based on the results of tumor molecular testing. Evaluation of the KRAS and NRAS gene status is mandatory for consideration of anti-epidermal growth factor recepto...
美国NCT数据库提供标题为Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program的临床试验登记信息,包括基本信息,试验详情,试验设计,试验分组,治疗终点,招募标准,联系人与地点等.
Birrer: Should every patient with endometrial cancer undergo molecular testing? What biomarkers are you testing for? For a neoadjuvant patient, are you doing it on the endometrial biopsy? What specifically are you ordering? And then how does that factor into your decision-making? Strauss: I ...
EP: 7.Molecular Testing at Diagnosis of Metastatic Breast Cancer EP: 8.Molecular Testing for Patients With Metastatic Relapse on or Within 1 Year of Adjuvant Endocrine Therapy EP: 9.Role of ctDNA in Metastatic Breast Cancer EP: 10.Applying Molecular Testing Results in Treatment Planning ...
In-house molecular testing has significant positive clinical impact. Faster TAT, cost effectiveness and better management of testing are major advantages of local testing that would enable broader access to precision therapy for underserved cancer patients.Cancer GeneticsThuy PhungJohn LarrimoreKathy Navia...
Molecular testing in breast cancer has changed how breast cancers are classified clinically as well as the way we determine what therapies may be most effective for individual patients. Single marker molecular tests such as HER2 testing by FISH have become part of standardized testing in all newly...
Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the... cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine ...